Microbiological assessment of polymyxin B components tested alone and in combination

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7823-7825

  Kassamali, Zahra ^a   Prince, Randall A ^b   Danziger, Larry H ^c   Rotschafer, John C ^d   Rhomberg, Paul R ^e   Jones, Ronald N ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B; POLYMYXIN B ISOLEUCINE; POLYMYXIN B3; POLYMYXIN DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; OCTANOIC ACID DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH DILUTION; DRUG ANTAGONISM; DRUG POTENTIATION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CAPRYLATES; DRUG SYNERGISM; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84954546047     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01021-15     Document Type: Article

References (14)

1. Orwa JA, Van Gerven A, Roets E, Hoogmartens J. 2000. Liquid chromatography of polymyxin B sulphate. J Chromatogr A 870:237-243. http: //dx.doi.org/10.1016/S0021-9673(99)00936-X.
2. Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. 2013. Polymyxins: wisdom does not always come with age. Clin Infect Dis 57: 877-883. http://dx.doi.org/10.1093/cid/cit367.
3. Tam VH, Cau H, Ledesma KR, Hu M. 2011. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother 55:4490-4491. http://dx.doi.org/10.1128/AAC.00119-11.
4. He J, Ledesma KR, Lam W, Figueroa DA, Lim TP, Chow DS, Tam VH. 2010. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents 35:308-310. http://dx.doi.org/10.1016/j.ijantimicag.2009.11.005.
5. Kassamali Z, Wang W, Jones RN, Rotschafer JC, Danziger LH, Prince RA. 2013. Is what you see, what you get? Product variation in clinical and reference formulations of polymyxin B, abstr 1119. Eur Cong Clin Microbiol Infect Dis (ECCMID), 27 to 30 April 2013, Berlin, Germany.
6. CLSI. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Jones RN, Fritsche TR, Moet GJ. 2008. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagn Microbiol Infect Dis 611:76-79.
9. Sader HS, Rhomberg PR, Flamm RK, Jones RN. 2012. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagn Microbiol Infect Dis 74:412-414. http: //dx.doi.org/10.1016/j.diagmicrobio.2012.08.025.
10. Hindler JA, Humphries RM. 2013. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol 51:1678-1684. http://dx.doi.org/10.1128/JCM.03385-12.
11. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão R, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093 /cid/cit334.
12. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298-1304. http: //dx.doi.org/10.1086/592577.
13. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. 2012. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 56:5724-5727. http://dx.doi.org/10.1128/AAC.01333-12.
14. Orwa JA, Govaerts C, Busson R, Roets E, Van Schepdael A, Hoogmartens J. 2001. Isolation and structural characterization of polymyxin B components. J Chromatogr A 912:369-373. http://dx.doi.org/10.1016 /S0021-9673(01)00585-4.